SAR 443809
Alternative Names: SAR-443809Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Sanofi
- Class Monoclonal antibodies; Urologics
- Mechanism of Action Complement factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(In volunteers) in USA (IV)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(In volunteers) in USA (SC)
- 10 Feb 2022 SAR 443809 is available for licensing as of 10 Feb 2022. https://www.sanofi.com/en/science-and-innovation/partnering/lets-partner